Circular RNAs As Genome Destabilisers In Human Disease
Funder
National Health and Medical Research Council
Funding Amount
$2,163,220.00
Summary
Mutation of genes are hallmarks of both cancer and neurological disorders. My research group has identified roles for circular RNAs in both these processes. Now, we must close the loop by investigating the mechanism of these processes. This will inform not only why these genes are commonly mutated, but by exploiting the highly stable circular RNAs they may provide early prognostic/diagnostic biomarkers and even represent novel therapeutic targets for cancer and Huntington’s disease.
Atypical femoral fractures (AFF) are uncommon, but catastrophic, complications of the anti-osteoporosis medications, bisphosphonates. We aim to identify patients either protected from, or at risk of, AFF by identifying changes in their bone geometry, structure and quality, and genes increasing risk of these fractures. In this way, these cheap and effective anti-osteoporosis treatments can be targeted to patients at the lowest risk of AFF and alternative treatments to those at highest risk.
Reducing The Burden Of Breast Cancer Through Precision Prevention, Targeted Treatment And Enhanced Survivorship
Funder
National Health and Medical Research Council
Funding Amount
$1,491,192.00
Summary
Breast cancer affects 1 in 8 Australian women. Of all the cancers, breast cancer results in the largest number of years of healthy life lost from death and illness. My research will reduce this unacceptable burden of breast cancer for women and their families. Spanning prevention, through treatment to survivorship, it will facilitate reduced breast cancer incidence, more effective treatments and enhanced understanding of the effects of new treatments on ovarian function and fertility.
Structural Biology And Therapeutic Targeting Of Axon Degeneration
Funder
National Health and Medical Research Council
Funding Amount
$1,512,250.00
Summary
The molecular mechanisms underlying SARM1 (sterile alpha and TIR 1) function will be investigated, which will allow design of inhibitors of axon degeneration, which can be developed into therapeutic agents for neurodegenerative disease. Outcomes are not only anticipated to support excellence in basic research, but have potential of assisting health sectors and the economy, by reducing the burden of prevalent neurodegenerative diseases such as peripheral neuropathies and traumatic brain injury.
Integration Of Novel Biological Targets/biomarkers In The Treatment Of Lethal Prostate Cancer
Funder
National Health and Medical Research Council
Funding Amount
$1,930,260.00
Summary
Prostate cancer (PC) remains a major cause of cancer-related death. Precision medicine is predicated on the principle of the right drug for the right patient at the right time. This program aims to assess/validate the ability of blood-based molecular markers to predict an individual patient’s response to different treatments and develop new drug strategies based on biological endpoints. Overall, this project has the potential to improve survival and quality of life in men with lethal PC.